NORTH CHICAGO, IL (STL.News) AbbVie (NYSE: ABBV) announced financial results for the third quarter ended September 30, 2020.

“We continue to be very well positioned for the long-term. Results from key growth products – including Skyrizi, Rinvoq and Ubrelvy – continue to track ahead of our expectations, our aesthetics portfolio is demonstrating a strong V-shaped recovery, our hematologic-oncology franchise is delivering double-digit growth and we’re advancing numerous attractive late-stage pipeline programs,” said Richard A. Gonzalez, chairman and chief executive officer, AbbVie.  “We are also executing effectively on Allergan integration initiatives with synergy and accretion targets tracking well.”

NOTE: this is NOT complete release.

View complete release:



STL.News is owned and operated by STL.News, LLC. We publish States Top Leading News. Our news is timely, unbiased and content is obtained direct from the source to obtain reliable information. Additionally, we will publish YouTube news video from major media companies.